Leerink Partners analyst Michael Schmidt reiterated an Outperform rating and lowered his price target on bluebird bio (NASDAQ: BLUE) to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE